Abstract LB-387: Efficacy and safety of AB928 plus modified FOLFOX-6 (mFOLFOX-6) in participants with metastatic colorectal cancer (mCRC): Initial results at the recommended dose for expansion (ARC-3)
Cecchini M, Modiano M, Braiteh F, Gardner O, Gilbert H, DiRenzo D, Seitz L, Walters M, Yin F, Woloski R, Paoloni M, Chung K. Abstract LB-387: Efficacy and safety of AB928 plus modified FOLFOX-6 (mFOLFOX-6) in participants with metastatic colorectal cancer (mCRC): Initial results at the recommended dose for expansion (ARC-3). Cancer Research 2020, 80: lb-387-lb-387. DOI: 10.1158/1538-7445.am2020-lb-387.Peer-Reviewed Original ResearchModified FOLFOX-6Metastatic colorectal cancerAdverse eventsPhase 1bFOLFOX-6Stable diseaseColorectal cancerAnti-tumor immune responseECOG performance status 0Recommended doseAssociated with disease controlExploratory biomarker analysesTumor shrinkage >Disease control rateDying cancer cellsGrade 3 AEsPerformance status 0Dose-escalation studyAdenosine receptor blockadeOpen-label studyAmerican Association for Cancer ResearchAdenosine receptor antagonistRelease of ATPNext gene sequencingAdenosine axisAbstract CT246: Consortium-IO: A safety and efficacy study of VE800 in combination with nivolumab in previously treated patients with select advanced metastatic cancers
Davar D, Wang J, Cecchini M, Wainberg Z, Gutierrez M, Turk A, Szabady R, Norman J, Olle B, Roberts B, Bobilev D. Abstract CT246: Consortium-IO: A safety and efficacy study of VE800 in combination with nivolumab in previously treated patients with select advanced metastatic cancers. Cancer Research 2020, 80: ct246-ct246. DOI: 10.1158/1538-7445.am2020-ct246.Peer-Reviewed Original ResearchPD-1 blockadeResponse to PD-1 blockadeDisease control rateDose-limiting toxicityProgression-free survivalDuration of responseOverall survivalTreated patientsResistance to PD-1 blockadeCD8+ T cell infiltrationCancer patientsCD103+ dendritic cellsCourses of oral vancomycinClinical activitySimon 2-stage designMajor histocompatibilityT cell infiltrationMicrosatellite-stablePhase I studyEfficacy studiesAmerican Association for Cancer ResearchMultiple tumor modelsAdvanced metastatic cancerSingle dose levelAnti-tumor activity